Literature DB >> 1315234

In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model.

L B Rice1, C T Eliopoulos, J D Yao, G M Eliopoulos, R C Moellering.   

Abstract

The in vivo activity of the combination of daptomycin and fosfomycin against a beta-lactamase-producing, highly gentamicin-resistant strain of Enterococcus faecalis in a relapse model of rat endocarditis was studied. Minimum inhibitory concentrations (MICs) (micrograms per milliliter) for these agents against this strain were 4 (daptomycin) and 16 (fosfomycin). Time-kill studies demonstrated synergistic bactericidal activity when daptomycin (0.5 micrograms/ml) and fosfomycin (32 micrograms/ml) were combined. There was no significant difference between the number of valves sterilized by daptomycin alone [six (35%) of 17 valves sterilized] and daptomycin+fosfomycin [ten (59%) of 17 valves sterilized] p = 0.3. These results suggest that the in vitro bactericidal synergism demonstrable between these two agents against strains of enterococci will not necessarily translate into greater therapeutic efficacy in clinical infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315234     DOI: 10.1016/0732-8893(92)90045-u

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

Review 1.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

2.  Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 3.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; H Lagler; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 6.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

Review 7.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

Review 8.  Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.

Authors:  Esther Benamu; Stanley Deresinski
Journal:  F1000Res       Date:  2018-01-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.